ArticleJournal of clinical microbiology2014
Clinical evaluation of multiple inflammation biomarkers for diagnosis and prognosis for patients with systemic inflammatory response syndrome.
Article in Journal of clinical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- The Diagnostic and Prognostic Value of suPAR in Patients with Sepsis: A Systematic Review and Meta-Analysis.Shock (Augusta, Ga.) · 2020Pooled it
- Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults.The Cochrane database of systematic reviews · 2019Pooled it
- Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.Scientific reports · 2016Pooled it
- Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster randomized interventional trial.Scandinavian journal of trauma, resuscitation and emergency medicine · 2016Trial
- Fibronectin mediates activin A-promoted human trophoblast migration and acquisition of endothelial-like phenotype.Cell communication and signaling : CCS · 2024Article
- Explainable Artificial Intelligence Helps in Understanding the Effect of Fibronectin on Survival of Sepsis.Cells · 2022Article
- Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update.Caspian journal of internal medicine · 2022Article
- Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit.Scientific reports · 2021Article
- Kidney involvement in coronavirus-associated diseases (Review).Experimental and therapeutic medicine · 2021Review
- Necrotizing Fasciitis: Pillaging the Acute Phase Response.The Journal of bone and joint surgery. American volume · 2020Review
- Plasma and Cellular Forms of Fibronectin as Prognostic Markers in Sepsis.Mediators of inflammation · 2020Article
- An Overview of Nucleic Acid Testing for the Novel Coronavirus SARS-CoV-2.Frontiers in medicine · 2020Review
- Article
- To What Extent Are the Terminal Stages of Sepsis, Septic Shock, Systemic Inflammatory Response Syndrome, and Multiple Organ Dysfunction Syndrome Actually Driven by a Prion/Amyloid Form of Fibrin?Seminars in thrombosis and hemostasis · 2018Review
- Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System.Theranostics · 2018Review
- Variation of Circulating Inflammatory Mediators in Staphylococcus aureus and Escherichia coli Bloodstream Infection.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis.SpringerPlus · 2016Article
- Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19.Frontiers in immunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A multiplexed biomarker bundle consisting of nine different inflammation markers was evaluated regarding their diagnostic and prognostic performances in 159 adult systemic inflammatory response syndrome (SIRS) patients enrolled at the emergency department. Fibronectin, interleukin-8 (IL-8), biotin, and neutrophil gelatinase-associated lipocalin (NGAL) were the most robust markers but were not superior to the already established markers IL-6, C-reactive protein (CRP), procalcitonin (PCT), and soluble urokinase plasminogen activator receptor (suPAR).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.